Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Harmony Biosciences Holdings Inc
HRMY
Healthcare
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance...
histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. It also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. It also develops ZYN002, a pharmaceutically manufactured synthetic cannabidiol. It is also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:HRMY)
New Post
View:
Posts & Comments
Threaded Posts
(170)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Aug 06, 2024 11:31am
Harmony Biosciences Reports Strong Second Quarter 2024 Finan
NEWS: $HRMY Harmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028WAKIX ® (pitolisant) Net
...more
(170)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Apr 30, 2024 1:15pm
Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Ad
News; $HRMY Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS AssetsHarmony Biosciences Acquires Epygenix
...more
(4)
•••
AviseAnalytics
X
View Profile
View Bullboard History
Post by
AviseAnalytics
on Jun 02, 2022 7:51am
PITOLISANT IS A “PORTFOLIO IN A PRODUCT” OPPORTUNITY!
Harmony Biosciences, Inc. (NASDAQ: HRMY) is a commercial-stage biopharmaceutical company developing novel therapeutics for rare and orphan diseases, focusing on central nervous system disorders.
...more
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Where to find Educational Resources for Beginner and Intermediate Investors
Red Cloud: Fall Mining Showcase 2024 Starting October 16 – Register Here